Sharechat Logo

AFT submits Maxigesic IV packaging data to the US FDA

Tuesday 18th April 2023

Text too small?

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV.


In a delay to the registration of the medicine in the US, the FDA requested in July 2022 additional data on the performance of Maxigesic IV’s primary packaging (the glass vial in which the medicine is stored and the vial’s stopper).


AFT along with its commercialisation partner Belgium’s Hyloris Pharmaceuticals has over the last year collated the data and submitted today.


AFT Managing Director Dr Hartley Atkinson said: “We believe the data we have submitted will satisfy the FDA’s requirements and remove the outstanding hurdle to registration. All going well we anticipate registration of the medicine this year and sales to follow shortly after.”


Maxigesic IV, is a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain. It has been developed in collaboration with Hyloris and is currently licensed in more than 100 countries across the globe. It has also been registered in 43 countries and launched in 19 countries including Australia, France, Germany, and Korea. The medicine is protected by several granted patents and pending patent applications.


Released for and on behalf of AFT Pharmaceuticals by Malcolm Tubby, Chief Financial Officer


Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232


Released for and on behalf of AFT Pharmaceuticals by Malcolm Tubby, Chief Financial Officer


About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information:[

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Me Today - Notice of Annual Shareholder Meeting
FSF - Director Scott St John to retire from Fonterra Board
Greenfern announces change in Chief Financial Officer
AIA Provision of Financial Assistance - Employee Share Plan
CBD - Recording and Presentation of Investor Call
CRP - Korella North Mining Lease Lodgement Approved
Genesis Energy launches new strategy
November 30th Morning Report
IFT270 - Interest Rate Reset